DDIs & Other Prescribing Issues, References

References Part III - Drug-drug Interactions and Other Prescribing Issues in PLWH

Cerrone M, Alfarisi O, Neary M, et al. Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. J Antimicrob Chemother 2019; 74:1670-8
PK study showing that coadministration of TAF 25 mg qd with rifampicin results in lower exposure of TAF but intracellular tenofovir diphosphate levels are still 4.2 fold higher than those observed with TDF even without rifampicin.

Hodge D, Back DJ, Gibbons S, Khoo S, Marzolini C. Pharmacokinetics and drug-drug interactions of intramuscular cabotegravir and rilpivirine. Clin Pharmacokinet 2021 Jul;60(7):835-853. doi: 10.1007/s40262-021-01005-1. Epub 2021 Apr 8.
This review provides insight on the im administration of drugs and summarizes DDI profiles after oral and im administration of CAB and RPV

American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 2019;67:674-94

Roskam-Kwint M, Bollen P, Colbers A, et al. Crushing of dolutegravir fixed dose combination tablets increases dolutegravir exposure. J Antimicrob Chemother 2018; 73(9):2430-2334.

Brown K, Thomas D, McKenney K et al. Impact of splitting or crushing on the relative bioavailability of the darunavir/cobicistat/emtricitabine/tenofovir alafenamide single tablet regimen. Clin Pharmacol Dev 2019; 8(4):541-8. https://www.medicines.org.uk/emc/

Ashley C, Dunleavy A, editors. The Renal Drug Handbook. 5th ed. Boca Raton:CRC Press;2019,

O’Mahony D et al. Age Ageing 2015. Good practice guidelines for the assessment and treatment of adults with gender dysphoria. Royal College of Psychiatrists, London, 2013, Document CR181

Good practice guidelines for the assessment and treatment of adults with gender dysphoria. Royal College of Psychiatrists, London, 2013, Document CR181

Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. Hembree WC et al. J Clin Endocrinol Metab, 2009, 94(9):3132-54

Guidelines for the primary and gender-affirming care of transgender and gender nonbinary people. Department of Family & Community Medicine, University of California, 2016

Endocrine care of transpeople part I. A review of cross-sex hormonal treatments, outcomes and adverse effects in transmen. Meriggiola MC, Gava G. Clin Endocrinol (Oxf). 2015, 83(5):597-606